Compare Illumina, Inc. (ILMN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Eli Lilly And Co — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while Eli Lilly And Co trades at $1,164.15 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 26× Illumina, Inc.'s market cap, and Eli Lilly And Co pays a 0.59% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Eli Lilly And Co for 93 Days on average.
| ILMN | LLY | |
|---|---|---|
Market Cap | $39.95B | $1.04T |
Volume | 3,169,503 | 3,064,878 |
Sector | Health | Health |
52-Week High | $293.69 | $1.28K |
52-Week Low | $91.00 | $799.57 |
Typical Hold Time | 83 Days | 93 Days |
Enterprise Value | $41.31B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
